Laekna's LAE124 to be Featured at Obesity Week 2026 in Washington, D.C.
Laekna, a leading biotechnology company, has announced an exciting development in the field of obesity treatment. At the upcoming Obesity Week 2026, the company will spotlight their innovative oral small-molecule, LAE124, which acts as a dual agonist for the Amylin and Calcitonin receptors. This presentation is set to take place during one of the most distinguished sessions focused on emerging weight-loss therapies, scheduled for November 15, 2026. The Obesity Week event is expected to see participation from over 4,300 researchers and clinicians from around the globe, indicating the significance of the event in the obesity research community.
Dr. Justin Gu, Laekna’s Chief Scientific Officer, emphasized the unique advantages of LAE124. Unlike other Amylin analogs that are predominantly peptide drugs requiring injections, this oral small molecule could provide a more convenient option for patients, potentially enhancing adherence to treatment. Research has shown that LAE124 yields a significant decrease in food intake and weight gain in studies with diet-induced obesity rats, underscoring its robust efficacy.
LAE124 is currently undergoing IND-enabling studies and has exhibited a favorable pharmacokinetic (PK) profile in preclinical trials. With a long half-life and high oral bioavailability, this medication is predicted to support once-daily dosing in humans, marking a significant advancement in the treatment landscape of obesity.
In addition to LAE124, Laekna is broadening its impact in metabolic diseases with a diverse pipeline that includes several drug candidates targeting various pathways, such as the ActRII receptor. The company’s commitment to innovative therapeutic approaches is evident in their acceleration of drug development across multiple targets, including those directed toward Amylin and UCN2 pathways.
LAE124’s presentation not only represents a pivotal moment for Laekna but also aligns with the theme of Obesity Week 2026, “Innovative Science to Transformational Care.” This theme resonates with the ongoing challenges faced in obesity management and reflects the growing emphasis on research and development of effective solutions. Through advanced studies and collaborations, Laekna hopes to redefine patient care in the obesity sector.
The poster presentation details highlight the following important aspects:
Laekna further prides itself on being a science-driven entity with over 20 innovative drug candidates under its proprietary rights. Focused on meeting the needs of patients suffering from major diseases, including metabolic disorders and oncology, the company is making strides towards commercializing their therapies, as indicated by the recent advancements in clinical trials for some of their key products.
Building on their foundation of scientific expertise and extensive knowledge of disease mechanisms, Laekna continues to thrive as a significant player in the biotechnology sector. Their comprehensive approach to developing effective and safe obesity treatments is pivotal in a field that desperately needs innovative solutions to combat the growing epidemic of obesity worldwide.
For further information on Laekna and their groundbreaking work, interested parties can visit their website or connect with them on LinkedIn.
Dr. Justin Gu, Laekna’s Chief Scientific Officer, emphasized the unique advantages of LAE124. Unlike other Amylin analogs that are predominantly peptide drugs requiring injections, this oral small molecule could provide a more convenient option for patients, potentially enhancing adherence to treatment. Research has shown that LAE124 yields a significant decrease in food intake and weight gain in studies with diet-induced obesity rats, underscoring its robust efficacy.
LAE124 is currently undergoing IND-enabling studies and has exhibited a favorable pharmacokinetic (PK) profile in preclinical trials. With a long half-life and high oral bioavailability, this medication is predicted to support once-daily dosing in humans, marking a significant advancement in the treatment landscape of obesity.
In addition to LAE124, Laekna is broadening its impact in metabolic diseases with a diverse pipeline that includes several drug candidates targeting various pathways, such as the ActRII receptor. The company’s commitment to innovative therapeutic approaches is evident in their acceleration of drug development across multiple targets, including those directed toward Amylin and UCN2 pathways.
LAE124’s presentation not only represents a pivotal moment for Laekna but also aligns with the theme of Obesity Week 2026, “Innovative Science to Transformational Care.” This theme resonates with the ongoing challenges faced in obesity management and reflects the growing emphasis on research and development of effective solutions. Through advanced studies and collaborations, Laekna hopes to redefine patient care in the obesity sector.
The poster presentation details highlight the following important aspects:
- - Poster Number: 465
- - Poster Title: LAE124: A Novel Oral Small-Molecule Dual Amylin/Calcitonin Receptor Agonist for Treatment of Obesity
- - Presentation Time: Sunday, November 15, from 2:30 PM to 3:30 PM EST
- - Location: Gaylord National Resort & Convention Center, Exhibit Hall BCD, Washington, D.C.
Laekna further prides itself on being a science-driven entity with over 20 innovative drug candidates under its proprietary rights. Focused on meeting the needs of patients suffering from major diseases, including metabolic disorders and oncology, the company is making strides towards commercializing their therapies, as indicated by the recent advancements in clinical trials for some of their key products.
Building on their foundation of scientific expertise and extensive knowledge of disease mechanisms, Laekna continues to thrive as a significant player in the biotechnology sector. Their comprehensive approach to developing effective and safe obesity treatments is pivotal in a field that desperately needs innovative solutions to combat the growing epidemic of obesity worldwide.
For further information on Laekna and their groundbreaking work, interested parties can visit their website or connect with them on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.